Siteman Kids is the First Site of Multicenter CAR-T Trial for Autoimmune Diseases
Access to the novel immunotherapy — which “has the potential for cure” — is the latest offering by the national leader in pediatric hematology, oncology, and cell therapies. Siteman Kids at St. Louis Children’s Hospital, along with WashU Medicine in St. Louis, is the first site to test a novel immunotherapy drug for the […]
New Phase 2 Clinical Trial Opens for Rare Leukemia/Lymphoma in Children
Off-the-shelf cellular therapy targets relapsed or refractory T-cell leukemia/lymphoma A potentially groundbreaking clinical trial is now open at Siteman Kids at St. Louis Children’s Hospital to evaluate an allogeneic, off-the-shelf cellular therapy designed to treat patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/LBL). Siteman Kids is one of […]
Treating Multiple Myeloma — New Immunotherapies
Multiple myeloma has long vexed medical researchers because of the cancer’s specific ability to both weaken and “hide” from a patient’s own immune system. The result is that while many treatments have been able to treat the disease for some time, patients subsequently relapse. But newer medications now can control the disease for extended […]
Novel Lymphoma Clinical Trials Underway
In just the past five years, the development of new therapeutics has changed the paradigm for the treatment of lymphomas, thereby improving outcomes and quality of life. As research continues, a major goal is to find more tolerable treatment options with higher efficacy. At Siteman Cancer Center, 35 open clinical trials are investigating novel immunotherapies, […]
Washington University to test ‘homegrown’ universal CAR T-cell therapy at Siteman Cancer Center
In early 2022, immunotherapy specialists at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine will begin a new clinical trial using off-the-shelf CAR T-cell therapy for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The therapy, developed by Washington University researchers at Siteman, incorporates many facets of the School […]